Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Harvard Business School
Express Scripts
McKesson
Merck

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for ADX-71149

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug ADX-71149: Patents, clinical trial progress, indications

ADX-71149 is an investigational drug.

There have been 7 clinical trials for ADX-71149. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2015.

The most common disease conditions in clinical trials are Narcolepsy, Syndrome, and Conjunctivitis. The leading clinical trial sponsors are Aldeyra Therapeutics, Inc., Jazz Pharmaceuticals, and ORA, Inc.

There are two US patents protecting this investigational drug and thirty-seven international patents.

Recent Clinical Trials for ADX-71149
TitleSponsorPhase
RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)Aldeyra Therapeutics, Inc.Phase 3
A Randomized, Double Masked, Clinical Study to Assess ADX-102 Ophthalmic Solution in Subjects With Dry Eye SyndromeAldeyra Therapeutics, Inc.Phase 2
A Phase 3 Study to Evaluate ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis.Aldeyra Therapeutics, Inc.Phase 3

See all ADX-71149 clinical trials

Clinical Trial Summary for ADX-71149

Top disease conditions for ADX-71149
Top clinical trial sponsors for ADX-71149

See all ADX-71149 clinical trials

US Patents for ADX-71149

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ADX-71149   See Pricing 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4'] bipyridinyl-2'-ones Janssen Pharmaceuticals, Inc. (Titusville, NJ) Addex Pharma SA (Geneva, CH)   See Pricing
ADX-71149   See Pricing 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2- '-ones Janssen Pharmaceuticals, Inc. (Titusville, NJ) Addex Pharma SA (Geneva, CH)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ADX-71149

Drugname Country Document Number Estimated Expiration Related US Patent
ADX-71149 Argentina 068511 2027-09-14   See Pricing
ADX-71149 Austria 496906 2027-09-14   See Pricing
ADX-71149 Australia 2008297878 2027-09-14   See Pricing
ADX-71149 Brazil PI0816767 2027-09-14   See Pricing
ADX-71149 Canada 2696948 2027-09-14   See Pricing
ADX-71149 China 101801951 2027-09-14   See Pricing
ADX-71149 China 103342695 2027-09-14   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Harvard Business School
Dow
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.